1st Quarter - Report · 2026

Filing UUID: 59b96ba1-7962-4274-a0d9-3f310e0475fd
Type: Q1 — 1st Quarter - Report
Period: first_quarter
Year: 2026
Posted: 2026-04-15 14:02:27
Income (reported): $40,000
Expenses (reported): —
Filing document: Open on lda.senate.gov

Registrant (lobbying firm)

THE NICKLES GROUP, LLC

Consulting firm.

Contact: KATHLEEN MCGHEE
Phone: +1 202-742-6990
Address: zip:20005, city:Washington, state:DC, street:601 13th St. NW Suite 250 N

Client

EMERGENT BIOSOLUTIONS

Pharmaceutical company.

State: MD
Country: US
Government-entity client: false
Effective date: 2014-12-15

Issues lobbied + lobbyists

`BUD` — Budget/Appropriations

Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield. Opioid and heroin addiction legislation, naloxone access and awareness.

Lobbyists: mr DONALD KENT

Government entities lobbied: SENATE

`HCR` — Health Issues

Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act, Funding for medical countermeasure enterprise including Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield, Opioid crisis legislation, naloxone access and awareness, FY2027 NDAA provisions related to biological and chemical defense and access to naloxone.

Lobbyists: mr DONALD KENT; MARY BETH SAVARY TAYLOR

Government entities lobbied: HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); SENATE

`DEF` — Defense

National Defense Authorization Act for FY2027, provisions related to biological and chemical defense and access to naloxone.